The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs

The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs

Jindong Dai,1 Xingming Zhang,1 Zhenhua Liu,1 Tingni Song,2 Xudong Zhu,1 Haoran Zhang,1 Mingpeng Wu,2 Xiang Li,1 Hao Zeng,1 Pengfei Shen1 1Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China; 2Department of Radiolo...

Full description

Bibliographic Details
Main Authors:	Dai J, Zhang X, Liu Z, Song T, Zhu X, Zhang H, Wu M, Li X, Zeng H, Shen P
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-02-01
Series:	Cancer Management and Research
Subjects:	tyrosine kinase inhibitor body fat component prognosis
Online Access:	https://www.dovepress.com/the-prognostic-value-of-body-fat-components-in-metastasis-renal-cell-c-peer-reviewed-article-CMAR

Similar Items

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
by: Wenxian Wang, et al.
Published: (2022-05-01)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
by: Kang Qin, et al.
Published: (2020-04-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
by: Yu Liu, et al.
Published: (2019-06-01)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
by: Chen-Yu Hu, et al.
Published: (2019-12-01)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
by: Di Wu, et al.
Published: (2022-04-01)

Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Ling MA, et al.
Published: (2013-06-01)

Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
by: Ze Zhang, et al.
Published: (2023-02-01)

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
by: Michele Malagola, et al.
Published: (2021-03-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
by: Wen-Ru Chou, et al.
Published: (2022-09-01)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
by: Sun T, et al.
Published: (2023-03-01)

Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment
by: Davide Frumento, et al.
Published: (2024-01-01)

Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience
by: Lucia Brilli, et al.
Published: (2021-01-01)

Research Progress of New Generation EGFR-TKIs after Third-generation
by: Yuanyuan LIU, et al.
Published: (2020-11-01)

Research Progress on the Combination Therapy of EGFR-TKIs and Metformin  in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer
by: Jiamin WANG, et al.
Published: (2023-11-01)

Skin Metastasis of Gastrointestinal Stromal Tumors: A Case Series and Literature Review
by: Liu P, et al.
Published: (2020-08-01)

Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report
by: Xingxing WANG, et al.
Published: (2015-09-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
by: H. Mohammad, et al.
Published: (2022-01-01)

Chromosomal Aberrations in Chronic Myeloid Leukemia: Response to Conventional TKIs and Risk of Blastic Transformation
by: Shafaq Maqsood, et al.
Published: (2021-03-01)

Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia
by: Alessandro Costa, et al.
Published: (2024-01-01)

Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs
by: Barbara eMelosky, et al.
Published: (2014-09-01)

The association of QTc prolongation with cardiovascular events in cancer patients taking tyrosine kinase inhibitors (TKIs)
by: Ismail Ghafary, et al.
Published: (2023-05-01)

Concomitant <i>TP53</i> Mutation Confers Worse Prognosis in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
by: Matteo Canale, et al.
Published: (2020-04-01)

Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2024-03-01)

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)

Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations
by: Chunxia Su, et al.
Published: (2022-07-01)

Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
by: Ziqiang Han, et al.
Published: (2022-12-01)

Abl family kinases in development and disease /
by: Koleske, Anthony J.
Published: (2006)

Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs  in Non-small Cell Lung Cancer
by: Shubin LI, et al.
Published: (2018-02-01)

Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma
by: Wen Cai, et al.
Published: (2017-05-01)

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
by: Peter Hillmen, et al.
Published: (2021-05-01)

Checkpoint molecule PD-1-assisted CD8+ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
by: Yao J, et al.
Published: (2018-09-01)

Evolving Patterns of Metastasis in Renal Cell Carcinoma
by: Justin Lin, et al.
Published: (2021-10-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Targeting FER Kinase Inhibits Melanoma Growth and Metastasis
by: Iordanka A. Ivanova, et al.
Published: (2019-03-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
by: Tzu-Hsuan Chiu, et al.
Published: (2021-09-01)